

Supplementary Tables

Supplementary Table 1. Clinical characteristics of the patients in cohort 1 (related to Figure 1)

| Patient-ID | Sex | Ethnicity | Age | Smoker | Comorbidities | Days from Admission to | WHO Scale |
|------------|--------|-----------|-------|-------------------|---|------------------------|-----------|
| 001 | male | caucasian | 70-79 | ex smoker (50 PY) | Hypertension, COPD, carotic artery stenosis, abdominal aortic replacement | 4 | 4 |
| 002 | male | caucasian | 50-59 | no | none | 20 | 8 |
| 003 | female | caucasian | 80-89 | no | colorectal cancer with pulmonary metastases | 10 | 8 |
| 004 | male | caucasian | 60-59 | no | Hypertension | 5 | 4 |
| 005 | male | caucasian | 40-49 | no | Asthma bronchiale, Psoriasis, Diabetes mellitus type II | 5 | 4 |
| 006 | male | caucasian | 70-79 | no | Hypertension | 1 | 4 |
| 007 | male | caucasian | 20-29 | no | none | - | 2 |
| H001 | male | caucasian | 50-59 | no | none | - | 0 |
| H002 | female | caucasian | 40-49 | no | none | - | 0 |
| H003 | male | caucasian | 50-59 | no | none | - | 0 |
| H004 | male | caucasian | 60-69 | no | none | - | 0 |
| 008 | female | caucasian | 60-69 | no | solid renal transplant, glomerulonephritis, | 1 | 4 |
| 009 | male | caucasian | 50-59 | no | NASH, Hypertriglyceridemia, Hypercholesterolemia, Hyperuricemia | 2 | 4 |
| 010 | male | caucasian | 70-79 | no | Renal insufficiency requiring dialysis, Hypertension, Diabetes mellitus type II, recurrent infection of chronic osteomyelitis, aortic sclerosis | 1 | 4 |
| 011 | female | caucasian | 70-79 | no | atrial fibrillation, condition after several strokes, right paraventricular mass with perifocal | - | 3 |
| 012 | female | caucasian | 50-59 | no | Covid-19 associated Aspergillosis, Candidaemia, AKI, Sepsis, Herpes labialis | 1 | 6 |
| 013 | female | caucasian | 60-69 | no | Obesity, Hypertension, Diabetes mellitus type II, Hypercholesterolemia, Hypothyreosis, breast cancer (20 years ago) | 1 | 4 |
| 014 | female | asian | 50-59 | no | Diabetes mellitus type II, schizophrenia, HIV | - | 5 |

Continued:

| Patient-ID | CRP range [mg/l] | IL-6 range [ng/l] | Ferritin range | Specific Treatment | Antiinfective Treatment | Other Medication | Max disease |
|------------|------------------|-------------------|----------------|------------------------------|--|---|----------------------|
| 001 | 9,0 - 100,1 | 14,1 - 135,0 | 710 - 2725 | Remdesivir | Sultamicillin | ASS, Ramipril, Atorvastatin, Tamsulosin, Ultibro | early convalescence |
| 002 | 12,96 - 358,0 | 52,6 - 2905 | 1295 - 8000 | Remdesivir | Piperacillin/Tazobactam | none | Critical (fatal) |
| 003 | 50,6 - 169,0 | 289,0 - 579,0 | 1118 - 1224 | none | Piperacillin/Tazobactam, Ciprofloxacin | Chemotherapy (FOLFIRI), metoprolol, Oipramol, Novaminsulfon, L-Thyroxin, Betahistin | Critical (fatal) |
| 004 | 34,3 - 241,0 | 41,7 - 324,0 | 1239 - 2354 | Remdesivir | Sultamicillin | Atorvastatin | complicated |
| 005 | 4,3 - 168,0 | 4,2 - 173,0 | 457 - 1184 | Remdesivir | none | Metformin, Actraphane, Oxis Inhaler, Spiolto, Flutide | late convalescence |
| 006 | 0,5 - 49,2 | 17,6 - 69,0 | 666 - 2378 | Remdesivir | none | Atenolol, Lisinopril | long-term follow-up |
| 007 | - | - | - | none | none | none | Not infected control |
| H001 | - | - | - | none | none | none | Not infected control |
| H002 | - | - | - | none | none | none | Not infected control |
| H003 | - | - | - | none | none | none | Not infected control |
| H004 | - | - | - | none | none | none | Not infected control |
| 008 | 41,9 - 217,3 | 9,0 - 43,0 | 909-1071 | none | | Ciclosporin, Azathioprin, | complicated |
| 009 | 5,5 - 115,7 | 4,0 - 38,0 | 1618-1901 | none | none | none | early convalescence |
| 010 | 41,7 - 287,6 | 31,0 - 574,0 | 802-4574 | none | none | Enalapril, Amlodipin, Metoprolol, Torem, ASS, Sevelamercarbon | complicated |
| 011 | 0,5 - 6,1 | 2,0 - 6,0 | 210 - 331 | none | none | Eliquis, HCT, Amlodipin, Valsartan, Simvastatin. | recovery |
| 012 | 2,1 - 347,5 | 62,0 - 311,0 | 368 - 1090 | Ribavirin +Lopinavir/r | Caspofungin | Bisoprolol, Ramipril, Famotidin, Enoxaparin | Critical |
| 013 | 1,0 - 144,2 | 48,0 - 70,0 | 815 - 2336 | Tocilizumab/Placebo (WA42380 | none | ASS, L-Thyroxin, Metformin, | complicated |
| 014 | 25,8 - 110,6 | 27,0 - 46,0 | 216 - 711 | Tocilizumab/Placebo (WA42380 | none | Triumeq, Trevicta | complicated |

Continued:

| Patient-ID | Sampling day since symptom onset | Longitudinal time point | PBMC | | PAX | Buffy/DNA methylome, GSA (d1) | Serum | |
|------------|----------------------------------|-------------------------|----------------|----------------------|-----|-------------------------------|------------|--------------------------|
| | | | Flow cytometry | single cell genomics | | | Antibodies | cytokine multiplex ELISA |
| 001 | 8 | d1 | | x | x | x | x | x |
| | 10 | d3 | x | x | x | x | x | x |
| | 15 | d8 | x | x | x | x | x | x |
| | 18 | d11 | | | x | x | x | x |
| | 21 | d14 | x | x | x | x | x | x |
| 002 | 19 | d1 | x | x | x | x | x | x |
| | 21 | d3 | x | x | x | x | x | x |
| 003 | 12 | d1 | x | x | x | x | x | x |
| 004 | 9 | d1 | x | x | x | x | x | x |
| | 11 | d3 | x | x | x | x | x | x |
| | 16 | d8 | x | x | x | x | x | x |
| 005 | 6 | d1 | x | x | x | x | x | x |
| | 8 | d3 | x | x | x | x | x | x |
| | 13 | d8 | x | x | x | x | x | x |
| | 16 | d11 | | | x | x | x | x |
| 006 | 12 | d1 | x | x | x | x | x | x |
| | 14 | d3 | x | x | x | x | x | x |
| | 19 | d8 | x | x | x | x | x | x |
| | 44 | d33 | x | x | x | | x | x |
| 007 | 45 | d1 | x | x | x | x | x | x |
| H001 | - | d1 | | | x | | | |
| H002 | - | d1 | | x | x | | | |
| H003 | - | d1 | | | x | | | |
| H004 | - | d1 | | x | x | | | |
| 008 | 18 | d1 | | x | x | | x | |
| | 21 | d4 | | | | | | |
| 009 | 18 | d1 | | x | x | | | |
| | 20 | d3 | | | x | | | |
| | 24 | d7 | | x | x | | | |
| 010 | 9 | d1 | | x | x | | x | |
| | 14 | d6 | | | x | | | |
| | 16 | d8 | | x | x | | | |
| | 20 | d12 | | | x | | x | |
| | 24 | d16 | | x | x | | | |
| 011 | 4 | d1 | | x | x | | x | |
| | 7 | d4 | | | x | | | |
| | 11 | d8 | | x | x | | x | |
| | 14 | d11 | | | x | | x | |
| 012 | 29 | d1 | | x | x | | | |
| | 36 | d8 | | x | x | | | |
| | 43 | d15 | | | x | | | |
| | 50 | d22 | | x | x | | | |
| | 57 | d29 | | | x | | | |
| 013 | 5 | d1 | | x | x | | x | |
| | 12 | d8 | | x | x | | | |
| 014 | 46 | d1 | | x | x | | x | |
| | 48 | d3 | | | x | | x | |